Form 4: Director Lockshin Granted PHIO Restricted Stock Units

Phio Pharmaceuticals Director Curtis Lockshin was granted 16,600 restricted stock units, vesting on the first anniversary of the grant.

Summary

• Director Curtis Lockshin of Phio Pharmaceuticals Corp. was granted 16,600 shares of common stock underlying a restricted stock unit.
• These shares will vest on the first annual anniversary of the grant date, February 5, 2026.
• The transaction price for these units was $0, indicating a grant rather than a purchase.
• Following this transaction, Lockshin beneficially owns 35,155 shares, which includes shares underlying unvested restricted stock units.
• The reported number of securities has been adjusted to reflect prior reverse stock splits.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it indicates continued alignment of a director's interests with the company's long-term performance through equity compensation.

Positives

• A director receiving restricted stock units aligns their interests with long-term shareholder value.
• The grant of 16,600 restricted stock units to Director Curtis Lockshin increases his beneficial ownership to 35,155 shares, demonstrating continued commitment.

Negatives

• No explicit negative information is contained within this Form 4 filing.

Risks

• The value of the restricted stock units is subject to the future performance of Phio Pharmaceuticals Corp.'s common stock.
• The vesting of the restricted stock units is contingent upon continued service, and forfeiture could occur if employment or directorship ceases before vesting.

Future Outlook

The restricted stock units are scheduled to vest on the first annual anniversary of the grant date, indicating a future milestone for the compensation.

Management Comments

• No direct quotes or paraphrased statements from management are included in this Form 4 filing, which is typical for this document type.

Industry Context

StockSavvy.ai notes that equity grants, such as restricted stock units, are a common form of executive and director compensation in the biotechnology and pharmaceutical sectors. These grants are often used to align the interests of insiders with long-term shareholder value, particularly in companies like Phio Pharmaceuticals that may be in development stages.

Comparison to Industry Standards

• Equity compensation for directors, particularly through restricted stock units, is a standard practice across publicly traded companies, including those in the biotech sector.
• The vesting schedule of one year for these RSUs is a common approach, similar to practices seen at companies like Moderna (MRNA) or BioNTech (BNTX) for certain types of employee or director equity awards, aiming to incentivize retention and long-term performance.
• The adjustment for prior reverse stock splits is a technical detail common in companies that have undergone such corporate actions, ensuring accurate reporting of beneficial ownership post-split, comparable to how companies like Sorrento Therapeutics (SRNEQ) or other small-cap biotechs might report.

Related Party Transactions

• The grant of restricted stock units to a director is a related party transaction, representing compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially incentivizing long-term value creation. It also represents a minor dilution over time as shares vest.
• Employees: No direct impact on employees is mentioned.

Next Steps

• The 16,600 restricted stock units granted to Director Curtis Lockshin are scheduled to vest on February 5, 2027 (one year after the grant date of February 5, 2026).

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a director, which is a standard compensation practice. While it signals continued insider alignment, it does not present new fundamental information that would significantly alter the investment thesis for Phio Pharmaceuticals Corp. Therefore, a "hold" recommendation is appropriate, maintaining current positions while awaiting more substantive operational or financial updates.

Keywords

Phio Pharmaceuticals, PHIO, Restricted Stock Units, RSU, Insider Ownership, Director Grant, Equity Compensation, SEC Form 4, Beneficial Ownership